An epidemic of an avian-origin H7N9 influenza virus has recently emerged in China, infecting 134 patients of which 45 have died. This is the first time that an influenza virus harboring an N9 serotype neuraminidase (NA) has been known to infect humans. H7N9 viruses are divergent and at least two distinct NAs and hemagglutinins (HAs) have been found, respectively, from clinical isolates. The prototypes of these viruses are A/Anhui/1/2013 and A/ Shanghai/1/2013. NAs from these two viruses are distinct as the A/Shanghai/1/2013 NA has an R294K substitution that can confer NA inhibitor oseltamivir resistance. Oseltamivir is by far the most commonly used anti-influenza drug due to its potency and high bioavailability. In this study, we show that an R294K substitution results in multidrug resistance with extreme oseltamivir resistance (over 100 000-fold) using protein-and virus-based assays. To determine the molecular basis for the inhibitor resistance, we solved high-resolution crystal structures of NAs from A/Anhui/1/2013 N9 (R294-containing) and A/Shanghai/1/2013 N9 (K294-containing). R294K substitution results in an unfavorable E276 conformation for oseltamivir binding, and consequently loss of inhibitor carboxylate interactions, which compromises the binding of all classical NA ligands/inhibitors. Moreover, we found that R294K substitution results in reduced NA catalytic efficiency along with lower viral fitness. This helps to explain why K294 has predominantly been found in clinical cases of H7N9 infection under the selective pressure of oseltamivir treatment and not in the dominant human-infecting viruses. This implies that oseltamivir can still be efficiently used in the treatment of H7N9 infections.
Introduction
Influenza A virus contains two major surface glycoproteins, hemagglutinin (HA) and neuraminidase (NA). HA initiates viral fusion by binding to sialic acid-containing receptors on the host cell and NA facilitates viral release by hydrolyzing the ketosidic bond of sialic acid. The balance of HA and NA activities is thought to be critical for influenza virus infectivity and transmissibility [1] . As an enzyme presented on the surface of the virus, NA is an ideal target for the design of competitive inhibitors [2] . Accordingly, there are currently four anti-NA inhibitors, oseltamivir, zanamivir, laninamivir and peramivir, which are approved for use in various countries [2] [3] [4] . Except NA-like molecule N10 from bat-origin influenza-like virus and influenza B NA, the nine remaining NA serotypes are classified into two groups according to their primary sequences [5] . N1, N4, N5 and N8 belong to group 1, while N2, N3, N6, N7 and N9 belong to group 2 [6] . N1 and N2 are the two most common serotypes found in epidemic and pandemic influenza viruses. In contrast, N9 has never before been observed in a human case of influenza virus infection.
Our previous studies reported that the NA gene of the novel H7N9 virus belongs to the Eurasian lineage [7] . Amino acid sequence alignment of A/Anhui/1/2013 N9 and A/Shanghai/1/2013 N9 with the previously characterized A/Tern/Australia/G70C/1975(H11N9) N9 illustrates that H7N9 N9 is missing five amino acids in the stem region ( Figure 1 ). This deletion has previously been found to be important for virus adaptation from migratory to terrestrial birds [8] . Moreover, there are 23 amino acid polymorphisms between the A/Anhui/1/2013 N9 and A/Tern/Australia/G70C/1975 N9 head regions. However, none of these variant amino acids are located in or nearby the N9 enzymatic active site.
There are only two residues that are different between A/Shanghai/1/2013 N9 and A/Anhui/1/2013 N9 ( Figure  1 ). One polymorphism (residue 40) is located in the stem region and the other (residue 294 (equivalent to residue 292 in N2)) is one of three highly-conserved arginine residues that interact with the sialic acid carboxylate and are critical for substrate binding and catalysis [9, 10] . Specifically, A/Anhui/1/2013 N9 contains R294 while A/ Shanghai/1/2013 N9 has K294 [9] . The R294K substitution has later been reported in 3 other H7N9 patients that were treated with oseltamivir [9, 11] . Therefore, we presumed that A/Shanghai/1/2013 N9 must have arisen from oseltamivir treatment although the full clinical data are not available.
Previous studies have found that N2 and in vitro generated avian H11N9 NA carrying the R294(292)K substitution are resistant to multiple NA inhibitors [12] [13] [14] [15] . However, naturally-occurring N9 carrying the R294K substitution has never been found in nature before. Furthermore, viruses carrying R294K exhibit compromised growth and fitness in vitro and were found to revert back to wild-type NA (R294) following multiple cycles of replication [16] . Moreover, these mutant viruses have been found to be 2-3 logs less infectious than wild-type virus and significantly less transmissible in a ferret model system [17] , suggesting that this substitution impairs NA activity and limits transmission ability.
The novel H7N9 virus has caused ongoing highly pathogenic influenza outbreaks throughout China. However, the structural and functional features of this naturally-occurring H7N9 NA remain unknown. Here, we report the crystal structure and functional characterization of two distinct human-derived influenza virus N9 proteins (from R294-containing A/Anhui/1/2013 virus and K294-containing A/Shanghai/1/2013 virus, respectively). Our findings demonstrate that the H7N9 R294K substitution not only confers multidrug resistance, but also decreases NA activity and impairs virus replication. This explains why H7N9 carrying R294K (A/Shanghai/1/2013 virus as its prototype) failed to be the dominant virus in this outbreak.
Results

The R294K substitution impairs H7N9 virus fitness and N9 enzymatic activity
To investigate the effect of the R294K substitution on H7N9 virus replication, we used reverse genetics to To provide more insights into the mechanism of how K294-containing N9 decreases viral fitness, we determined the relative activity and Michaelis-Menten (Km) constants of soluble recombinant N9 proteins and viruses generated by reverse genetics. In both systems, A/Shanghai/2013 N9 (K294-containing) shows lower activity and much higher Km values relative to A/Anhui/1/2013 N9 (R294-containing) ( Table 1 
The R294K substitution in N9 from epidemic H7N9 confers multidrug resistance
The sensitivity of N9 to four classical NA inhibitors was determined using both soluble recombinant N9 and H7N9 viruses. Remarkably, Shanghai virus (K294-containing) displayed extreme resistance to oseltamivir carboxylate (271 860-fold). In the case of zanamivir, laninamivir and peramivir, the R294K mutation conferred less resistance relative to oseltamivir carboxylate (Table 1) . For purified Shanghai N9, the IC 50 values for zanamivir, laninamivir and peramivir were 75.7 nM, 89.6 nM and 184.7 nM, respectively. More potent inhibition of Anhui N9 was apparent with the IC 50 values of 0.41 nM, 3.24 nM and 0.40 nM for zanamivir, laninamivir 
Structural basis of multidrug resistance in the N9 of human-infecting H7N9
To gain insight into the structural basis of the N9-R294K drug-resistant substitution, high-resolution crystal structures of Anhui N9 and Shanghai N9 were solved. N9 crystals were also soaked with classical NA inhibitors to solve the N9-inhibitor complex structures. In the uncomplexed Shanghai N9 and Anhui N9 structures, all active site residues adopt the same typical conformations except E276 and K/R294 (Figure 4 ). E276 is a flexible residue that adopts two distinct conformations in known NA structures, one oriented towards the center of the NA active site and the other oriented toward R224. In Anhui N9, E276 forms a salt bridge with R224, the conformation favorable for the binding of the oseltamivir carboxylate hydrophobic pentyloxy group. In contrast, Shanghai N9 contains a K294, which forms a salt bridge (2.95 Å in the uncomplexed Shanghai N9 structure, 3.12 Å in the Shanghai N9-oseltamivir carboxylate complex) with E276, forcing E276 to adopt a conformation that interferes with the binding of the oseltamivir pentyloxy group.
In the Shanghai and Anhui N9-oseltamivir carboxylate complex structures, E276 adopts the same conformations as in the uncomplexed structures ( Figure 5A ). Therefore, Anhui N9 is able to accommodate oseltamivir carboxylate well with a hydrophobic pocket formed by the favorable conformation of E276. However, in Shanghai N9, E276 is oriented toward the oseltamivir carboxylate hydrophobic pentyloxy group. This unfavorable interaction pushes the oseltamivir carboxylate pentyloxy group away from the active site (by 2.98 Å).
Interestingly, despite containing a pentyloxy group like oseltamivir, in the Shanghai N9-peramivir complex structure, E276 is still able to adopt the optimal conformation where it forms a salt bridge with R224 ( Figure  5B ). This is in agreement with our inhibition data showing that peramivir resistance is not as severe as oseltamivir resistance. We speculate that this is due to a smaller cyclopentane ring that affords more distance between the peramivir pentyloxy group and E276.
In addition, Shanghai N9 K294 is approximately 1.5 Å further from the inhibitor carboxylate, further contributing to a weaker binding mode. The smaller lysine residue in position 294 also results in the addition of two water molecules between K294 and the inhibitor carboxylate ( Figure 5 ). This loss of a direct inhibitor carboxylate-K294 interaction is also observed in the Shanghai N9 complex structures with zanamivir, laninamivir and peramivir, explaining why Shanghai N9 also displays mild resistance to these inhibitors. Furthermore, the tri- Figure 4 Comparison of Anhui N9 and Shanghai N9 uncomplexed active sites. In Anhui N9 (bright orange), R294 is able to hydrogen-bond with the key catalytic residues, Y406 and E277. However, R294 is out of range to interact with E276, which is oriented toward R224, a conformation favorable for oseltamivir carboxylate binding. E276 forms a salt bridge with R224. In Shanghai N9 (palecyan), K294 is out of range to form any typical hydrogen bonds with Y406 or E277. Instead, K294 is able to form a salt bridge with E276, which is oriented toward K294, a conformation unfavorable for oseltamivir carboxylate binding. arginyl-carboxylate interaction is thought to be a major factor for distorting the sialic acid pyranose ring from a chair to a boat conformation. Current data indicate that influenza NA first binds α2,3-or α2,6-linked glycoconjugates in a 2 C 5 chair conformation; the substrate then undergoes a conformation change to form a boat conformation and Tyr406 attacks the anomeric center, leading to glycosidic bond cleavage [18] . Therefore, R294 is likely a key residue in the NA catalytic mechanism and it is not surprising that N9 from A/Shanghai/1/2013 H7N9, which cannot form a K294-carboxylate interaction, has much lower NA activity compared to A/Anhui/1/2013. 
Discussion
Except N7, crystal structures for all typical influenza A NA serotypes are currently available in the Protein Data Bank (www.pdb.org). Some interesting structural differences between each serotype have been revealed through structural analysis. For example, group 1 influenza A NAs (N1, N4, N5 and N8) have been found to contain an additional cavity (150-cavity) adjacent to their active site, whereas all group 2 NAs with known structures (N2, N3, N6 and N9) lack this cavity [6] . Yet, although the N1s from H5N1 and 1918 H1N1 contain a 150-cav-ity, the N1 from the 2009 pandemic H1N1 does not [19] . This illustrates that there may be significant structural differences even within each NA serotype and highlights the importance of the structural analysis of novel NA proteins like N9 from H7N9.
Influenza NA inhibitor development is regarded as a classical example of structure-based drug design and the continued structural analysis of influenza NAs has contributed greatly to the design and evaluation of effective anti-influenza agents. As vaccines are still under development for the H7N9 virus, NA inhibitors are very important options for the treatment of H7N9 patients. In fact, oseltamivir treatment within 48 h of the disease onset has been recommended by the Chinese Center for Disease Control and Prevention. This practice has saved many lives. Therefore, the structural analysis of H7N9 NA is crucial for directing drug development and clinical administration of NA inhibitors for H7N9 patients.
It is clear that N9 proteins from early clinical isolates are divergent and an oseltamivir-resistant K294-containing N9 was identified from the first few isolates. N9 from A/Shanghai/1/2013 is the prototype in this regard although the history of inhibitor use for this patient is not clear. It is reported that in some clinical cases of H7N9 infection treated with oseltamivir, viruses carrying an R294K multidrug-resistant substitution in their N9 proteins have been isolated [11] . R294 is one of the three key conserved active site arginines that surround the carboxylate group of sialic acid. This tri-arginyl cluster is thought to be a major factor for distorting the sialic acid pyranose ring from a chair to a boat conformation, a critical step for influenza NA to catalyze the hydrolytic cleavage of terminal sialic acid from α2,3-or α2,6-linked glycoconjugates [10, 18] . Therefore, it is not surprising that N9 from A/Shanghai/1/2013 H7N9 has much lower NA activity and that R294K has never been found before in a wild-type N9 variant, though laboratory artificial drug-present passages yielded an R294K N9 [20] .
The knowledge that the Shanghai H7N9 viruses may contain an R294K substitution in their NA protein is critical for directing future drug administration in H7N9 patients. In these cases, oseltamivir should be used with caution, as it is > 100 000 times less effective against the R294K-containing H7N9. This is at a level much higher than even the prevalent H274Y oseltamivir-resistant substitution found in N1 viruses, which results in up to 1 200-fold resistance [21] . Of the 4 reported patients with the R294K substitution, 2 have died and 1 has remained hospitalized [9, 11] . All of these patients were only reported to be treated with oseltamivir and not with any of the other available classical NA inhibitors. Therefore, the drug-resistant mutations should be monitored vigilantly in H7N9 viruses in order to help administer the most effective drugs available and help to prevent unnecessary loss of human lives. Our results of low replication rate of the viruses with K294-containing N9 demonstrate that these viruses are less fit and cannot survive long, therefore oseltamivir is still a good inhibitor for the treatment of H7N9 patients.
Materials and Methods
Generation and growth of recombinant viruses
Recombinant viruses were generated by reverse genetics using previously described methods [22, 23] . For the Anhui virus, all eight segments stemmed from the isolated virus. For the Shanghai virus, HA and NA segments were from A/Shanghai/1/2013 virus, while the other internal gene segments were the same as the Anhui virus. For the H9N2 systems, A/Chicken/Shandong/lx1023/2007 (H9N2) internal genes were used as the backbone [24] , while HA and NA segments were from A/Anhui/1/2013 virus (H9N2-Anhui) or from A/Shanghai/1/2013 virus (H9N2-Shanghai). Replication curves were generated by inoculating MDCK cells at a multiplicity of infection (MOI) of 0.001 50% tissue culture infective doses (TCID 50 ) per cell. Supernatants were collected at 12, 24, 36, 48, 72 and 84 h post infection and the virus titers were determined by the Reed-Muench method [25] .
Neuraminidase production and crystallization experiments
Purified N9 was prepared in an insect/baculovirus expression system as previously reported [4, 19, 26, 27] . Crystallization conditions were screened using sitting drop vapor diffusion technique, with 1 µL of 8 mg/ml N9 protein mixed with 1 µL of reservoir solution. Anhui N9 crystals were obtained in the condition of 0.1 M MES monohydrate pH 6.0 and 14% w/v Polyethylene glycol 4000. Shanghai N9 crystals were obtained in the condition of 5% v/v(±)-2-Methyl-2,4-pentanediol, 0.1 M HEPES pH 7.5 and 10% Polyethylene glycol 10000. NA crystals were incubated in the mother liquor containing 20 mM inhibitor (oseltamivir carboxylate, zanamivir or laninamivir) or 10 mM peramivir, and then flash-cooled at 100 K. N9 crystals were cryoprotected and then flash-cooled at 100 K. Diffraction data were collected at Shanghai Synchrotron Radiation Facility beamline BL17U. Diffraction data were processed and scaled using HKL2000 [28] . The structure of Anhui N9 was solved by molecular replacement using the A/tern/Australia/G70C/1975 H11N9 N9 molecule (PDB 7NN9) as the search model with Phaser [29] in the CCP4 program suite [30] . The structure of Shanghai N9 was determined by molecular replacement using the solved Anhui N9 structure. Extensive model building was performed manually with COOT [31] , and restrained refinement was performed using REFMAC5 [32] . Further rounds of refinement were performed using the phenix.refine program implemented in the PHENIX package with energy minimization, isotropic ADP refinement and bulk solvent modeling [33] . The stereochemical quality of the final model was assessed with PROCHECK [34] . Crystallographic data and refinement statistics are shown in Table 2 . Completeness 100 (100) 100 (99.9) 100 (100) 100 (100) 100 (100) 96.9 (99.9) 99.9 (100) 100 (100) 100 (100) 100 (100) (%) 
